uniQure to Acquire Corlieve Therapeutics for $55M

Share this
uniQure to Acquire Corlieve Therapeutics for $55M

uniQure to Acquire Corlieve Therapeutics for $55M


  • Corlieve to receive $55M upfront in cash and is eligible to receive $52.1M as development milestones for P-I/II and $191M for P-III development and the approvals of AMT-260 in the US and EU. the transaction is anticipated to be completed in Q3’21
  • The acquisition will foster Corlieve lead program- AMT-260- and allows to expands uniQure’s pipeline of innovative gene therapies to treat neurological disorders by using miRNA Silencing Technology
  • Corlieve has a license agreement with REGENXBIO that includes an exclusive license to AAV9 for the specific genetic target of AMT-260. REGENXBIO received equity in Corlieve and is eligible to receive milestone payments & royalties on net sales of AMT-260

Ref: Globe Newswire | Image: PR Newswire

Click here to­ read the full press release 


Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions